Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / FDA - Page 11

FDA

Moderna announced FDA authorization of booster dose of  COVID-19 vaccine in the U.S.
Biotechnology | COVID-19 | FDA | Infectious Disease

Moderna announced FDA authorization of booster dose of COVID-19 vaccine in the U.S.

On Oct. 20, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized for emergency…

Read More Moderna announced FDA authorization of booster dose of COVID-19 vaccine in the U.S.Continue

Johnson & Johnson COVID-19 vaccine booster shot authorized for Emergency Use by U.S. FDA
COVID-19 | FDA | Life Science History

Johnson & Johnson COVID-19 vaccine booster shot authorized for Emergency Use by U.S. FDA

On Oct. 20, 2021, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) had issued Emergency…

Read More Johnson & Johnson COVID-19 vaccine booster shot authorized for Emergency Use by U.S. FDAContinue

FDA approved naloxone injection to counteract opioid overdoses
FDA | Life Science History

FDA approved naloxone injection to counteract opioid overdoses

On Oct. 18, 2021, the Food and Drug Administration approved ZIMHI (naloxone hydrochloride) injection as an additional option…

Read More FDA approved naloxone injection to counteract opioid overdosesContinue

U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populations
Biotechnology | FDA | HIV | Therapeutics

U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populations

On Oct. 18, 2021, Gilead Sciences announced that the Food and Drug Administration had approved a new low-dose…

Read More U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populationsContinue

FDA approved Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics

FDA approved Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

On Oct. 15, 2021, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Tecentriq (atezolizumab)…

Read More FDA approved Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancerContinue

Moderna announced FDA Advisory Committee unanimously voted in support of EUA for booster dose of COVID-19 vaccine
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna announced FDA Advisory Committee unanimously voted in support of EUA for booster dose of COVID-19 vaccine

On Oct. 14, 2021, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…

Read More Moderna announced FDA Advisory Committee unanimously voted in support of EUA for booster dose of COVID-19 vaccineContinue

FDA accepted REGEN-COVᆴ (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19
COVID-19 | FDA | Life Science History

FDA accepted REGEN-COVᆴ (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19

On Oct. 14, 2021, Regeneron announced that the U.S. Food and Drug Administration (FDA) had accepted for priority…

Read More FDA accepted REGEN-COVᆴ (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19Continue

Merck and Ridgeback announced Submission of EUA to the FDA for Molnupiravir, an Investigational Oral antiviral medicine, for treatment of COVID-19
COVID-19 | FDA | Life Science History

Merck and Ridgeback announced Submission of EUA to the FDA for Molnupiravir, an Investigational Oral antiviral medicine, for treatment of COVID-19

On Oct. 11, 2021, Merck and Ridgeback Biotherapeutics announced that Merck had submitted an Emergency Use Authorization (EUA)…

Read More Merck and Ridgeback announced Submission of EUA to the FDA for Molnupiravir, an Investigational Oral antiviral medicine, for treatment of COVID-19Continue

PerkinElmer received FDA Emergency Use Authorization for respiratory SARS-CoV-2 panel
Biotechnology | COVID-19 | FDA | Infectious Disease | Influenza | Therapeutics

PerkinElmer received FDA Emergency Use Authorization for respiratory SARS-CoV-2 panel

On Oct. 7, 2021, PerkinElmer announced that the U.S. Food and Drug Administration (FDA) had issued Emergency Use…

Read More PerkinElmer received FDA Emergency Use Authorization for respiratory SARS-CoV-2 panelContinue

EUROIMMUN anti-SARS-CoV-2 S1 curve ELISA received FDA Emergency Use Authorization
COVID-19 | Diagnostics | FDA

EUROIMMUN anti-SARS-CoV-2 S1 curve ELISA received FDA Emergency Use Authorization

On Oct. 5, 2021, PerkinElmer announced that the U.S. Food and Drug Administration had provided Emergency Use Authorization…

Read More EUROIMMUN anti-SARS-CoV-2 S1 curve ELISA received FDA Emergency Use AuthorizationContinue

Johnson & Johnson submitted EUA amendment to FDA to support booster of single-shot COVID-19 vaccine
COVID-19 | FDA | Life Science History

Johnson & Johnson submitted EUA amendment to FDA to support booster of single-shot COVID-19 vaccine

On Oct. 5, 2021, Johnson & Johnson announced it had submitted data to the U.S. Food and Drug…

Read More Johnson & Johnson submitted EUA amendment to FDA to support booster of single-shot COVID-19 vaccineContinue

Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 study
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics

Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 study

On Oct. 1, 2021, Merck and Ridgeback Biotherapeutics announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine,…

Read More Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 studyContinue

FDA approved Kiteメs Tecartusᆴ as first and only Car T for adults with Relapsed or Refractory B-cell ALL
FDA | Life Science History

FDA approved Kiteメs Tecartusᆴ as first and only Car T for adults with Relapsed or Refractory B-cell ALL

On Oct. 1, 2021, Kite, a Gilead Company, announced the U.S. Food and Drug Administration had granted approval…

Read More FDA approved Kiteメs Tecartusᆴ as first and only Car T for adults with Relapsed or Refractory B-cell ALLContinue

U.S. FDA cleared Naeotom Alpha, worldメs first photon-counting computer tomograph
FDA | Life Science History

U.S. FDA cleared Naeotom Alpha, worldメs first photon-counting computer tomograph

On Sept. 30 2021, Siemens Healthineers announced the Food and Drug Administration (FDA) 510 (k) clearance of the…

Read More U.S. FDA cleared Naeotom Alpha, worldメs first photon-counting computer tomographContinue

Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccine
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics

Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccine

On Sept. 29, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…

Read More Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccineContinue

Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to
COVID-19 | FDA | Life Science History

Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to <12 years of age

On Sept. 28, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…

Read More Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to <12 years of ageContinue

Pfizer and BioNTech received first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine booster
COVID-19 | FDA | Life Science History

Pfizer and BioNTech received first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine booster

On Sept. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) has authorized…

Read More Pfizer and BioNTech received first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine boosterContinue

OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA Waiver
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease

OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA Waiver

On Sept. 23, 2021, OraSure Technologies and the Biomedical Advanced Research Development Authority (BARDA) announced up to $13.6…

Read More OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA WaiverContinue

InBios received FDA EUA for COVID-19 IgG antibody rapid test
Biotechnology | COVID-19 | Diagnostics | FDA

InBios received FDA EUA for COVID-19 IgG antibody rapid test

On Sept. 15, 2021, InBios announced that it had received Emergency Use Authorization from the U.S. Food and…

Read More InBios received FDA EUA for COVID-19 IgG antibody rapid testContinue

FDA declined Humanigenメs Emergency Use Authorization request for lenzilumab in hospitalized COVID-19 patients
COVID-19 | FDA | Life Science History

FDA declined Humanigenメs Emergency Use Authorization request for lenzilumab in hospitalized COVID-19 patients

On Sept. 9, 2021, Humanigen announced the U.S. FDA had declined its request for emergency use authorization of…

Read More FDA declined Humanigenメs Emergency Use Authorization request for lenzilumab in hospitalized COVID-19 patientsContinue

AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical study of Ampligen for post-COVID-19 cognitive dysfunction
COVID-19 | FDA | Life Science History

AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical study of Ampligen for post-COVID-19 cognitive dysfunction

On Sept. 8, 2021, AIM ImmunoTech announced that is had submitted a Pre-Investigational New Drug application (Pre-IND) to…

Read More AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical study of Ampligen for post-COVID-19 cognitive dysfunctionContinue

Pfizer and BioNTech submitted a variation to EMA with data in support of a booster dose of COMIRNATY
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech submitted a variation to EMA with data in support of a booster dose of COMIRNATY

On Sept. 6, 2021, Pfizer and BioNTech announced that they had submitted a variation to the European Medicines…

Read More Pfizer and BioNTech submitted a variation to EMA with data in support of a booster dose of COMIRNATYContinue

Moderna announced submission of initial data to U.S. FDA for Its COVID-19 vaccine booster
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna announced submission of initial data to U.S. FDA for Its COVID-19 vaccine booster

On Sept. 1, 2021, Moderna announced it had initiated its submission to the U.S. Food and Drug Administration…

Read More Moderna announced submission of initial data to U.S. FDA for Its COVID-19 vaccine boosterContinue

Moderna completed submission of BLA to the Food and Drug Administration for its COVID-19 vaccine
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna completed submission of BLA to the Food and Drug Administration for its COVID-19 vaccine

On Aug. 25, 2021, Moderna announced it had completed the rolling submission process for its Biologics License Application…

Read More Moderna completed submission of BLA to the Food and Drug Administration for its COVID-19 vaccineContinue

BD received EUA for first at-home COVID-19 test to use smartphone to interpret, deliver results
COVID-19 | Diagnostics | FDA | Medical Device

BD received EUA for first at-home COVID-19 test to use smartphone to interpret, deliver results

On Aug. 25, 2021, BD (Becton, Dickinson) announced the U.S. Food and Drug Administration (FDA) had issued an…

Read More BD received EUA for first at-home COVID-19 test to use smartphone to interpret, deliver resultsContinue

Pfizer and BioNTech initiated rolling submission of SBLA to U.S. FDA for booster dose of COMIRNATY in individuals 16 and Older
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics

Pfizer and BioNTech initiated rolling submission of SBLA to U.S. FDA for booster dose of COMIRNATY in individuals 16 and Older

On Aug. 25, 2021, Pfizer and BioNTech announced the initiation of a supplemental Biologics License Application (sBLA) to…

Read More Pfizer and BioNTech initiated rolling submission of SBLA to U.S. FDA for booster dose of COMIRNATY in individuals 16 and OlderContinue

U.S. FDA approved first COVID-19 vaccine
COVID-19 | FDA | Vaccine

U.S. FDA approved first COVID-19 vaccine

On Aug. 23, 2021, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine, known…

Read More U.S. FDA approved first COVID-19 vaccineContinue

Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full U.S. FDA approval for individuals 16 years and older
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics

Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full U.S. FDA approval for individuals 16 years and older

On Aug. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) approved the…

Read More Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full U.S. FDA approval for individuals 16 years and olderContinue

Pfizer and BioNTech announced submission of initial data to FDA to support booster dose of COVID-19 vaccine
COVID-19 | FDA | Life Science History

Pfizer and BioNTech announced submission of initial data to FDA to support booster dose of COVID-19 vaccine

On Aug. 16, 2021, Pfizer and BioNTech announced that they had submitted Phase 1 data to the U.S….

Read More Pfizer and BioNTech announced submission of initial data to FDA to support booster dose of COVID-19 vaccineContinue

ADMA Biologics received FDA approval for plasma collection facility in Maryville, TN
FDA | Life Science History

ADMA Biologics received FDA approval for plasma collection facility in Maryville, TN

On Aug. 16, 2021, ADMA Biologics announced that it had received U.S. Food and Drug Administration approval for…

Read More ADMA Biologics received FDA approval for plasma collection facility in Maryville, TNContinue

Page navigation

Previous PagePrevious 1 … 9 10 11 12 13 … 41 Next PageNext
  • Categories
  • Timeline
  • Aesthetics
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cardiology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemistry
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Quantum
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Banner Advertising

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search